Compare Elastic NV (ESTC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Sana Biotechnology Inc — how do they compare? Elastic NV trades at $98.23 (market cap $10.00B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Elastic NV is far larger — about 12× Sana Biotechnology Inc's market cap, and Elastic NV is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Sana Biotechnology Inc for 23 Days on average.
| ESTC | SANA | |
|---|---|---|
Market Cap | $10.00B | $836.71M |
Volume | 1,610,337 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $99.91 | $5.92 |
52-Week Low | $43.30 | $2.68 |
Typical Hold Time | 10 Days | 23 Days |
Enterprise Value | $9.14B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $95.26, up 2.32% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches, including a new metrics platform and serverless vector database, highlight innovation in AI and observability. Revenue growth is projected to increase from $1.48B in 2025 to $1.8B in 2026, with net income turning positive to $376M.
The outlook is positive, driven by product momentum and earnings beats, but risks include high valuation multiples and insider selling. The consensus price target of $79.50 suggests caution, though the high target of $120.00 indicates upside potential. Investors should weigh strong fundamentals against valuation concerns and market volatility.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
